Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Files An 8-K Financial Statements and Exhibits
Item 9.01(a)(4) of Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(a) Financial statements of businesses acquired.
The audited special purpose financial information for the RHOFADE product comprised of the special purpose statement of assets acquired and liabilities assumed as of December 31, 2017, the special purpose statement of revenues and direct expenses for the year ended December 31, 2017, and the related notes,is filed as Exhibit 99.1 to this Current Report on Form 8-K/A and incorporated herein by reference.
The unaudited special purpose financial information for the RHOFADE product comprised of the special purpose statement of assets acquired and liabilities assumed as of September 30, 2018 and December 31, 2017, the special purpose statement of revenues and direct expenses for the nine months ended September 30, 2018 and 2017, and the related notes,is filed as Exhibit 99.2 to this Current Report on Form 8-K/A and incorporated herein by reference.
(b) Pro forma financial information.
The unaudited pro forma condensed combined financial statements of the Company comprised of the pro forma condensed combined balance sheet as of September 30, 2018, the pro forma condensed combined statement of operations for the nine months ended September 30, 2018, the pro forma condensed combined statement of operations for the year ended December 31, 2017, and the related notes, is filed as Exhibit 99.3 to this Current Report on Form 8-K/A and incorporated herein by reference.
(d)Exhibits.
Aclaris Therapeutics, Inc. Exhibit
EX-23.1 2 ex-23d1.htm EX-23.1 acrs_Ex23_1 Exhibit 23.1 CONSENT OF INDEPENDENT AUDITORS We hereby consent to the incorporation by reference in the Registration Statements on Forms S-3 (No. 333-212095) and S-8 (No. 333-223922,…
To view the full exhibit click here
About Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Aclaris Therapeutics, Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK). It has completed approximately three Phase II clinical trials of A-101. It has initiated over two multi-center, double blind Phase III clinical trials and an open label Phase III clinical trial of A-101 in patients with SK. It also intends to develop A-101 as a prescription treatment for common warts, also known as verruca vulgaris, and A-102, a gel dosage form of hydrogen peroxide, as a prescription treatment for SK and common warts. It has initiated a Phase II clinical trial to evaluate A-101 for the treatment of common warts.
